SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Rigel Pharmaceuticals, Inc. (RIGL)
An SI Board Since November 2000
Posts SubjectMarks Bans Symbol
566 39 0 RIGL
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
516[FosD TASKi3] >>Arthritis Rheum. 2011 Feb;63(2):337-45. doi: 10.1002/art.tuck-2/1/2011
515[Fostamatinib, a Syk-Kinase Inhibitor, Does Not Affect Methotrexate Pharmacokinetuck-1/7/2011
514THANKS!mopgcw-12/30/2010
513I posted notes on iHub regarding RIGL's presentation at Piper on 12/1/10 (semcbio-12/30/2010
512Rigel Announces Third Quarter 2010 Financial Results Newswire - Tuesday 11/02/20mopgcw-11/4/2010
511good question, i think this placebo response has been one of the issues dogging mopgcw-10/30/2010
510This Taski3 trial analysis notes unusually high placebo response, and suggests ttuck-10/30/2010
509I looked at responses to your original post, and agree with biomaven's assesscaram(o)uche-10/22/2010
508Thanks Dew! I was wondering what the issue was.mcbio-10/22/2010
507Housekeeping note: Links on SI are clickable only if you skip a space before andDewDiligence_on_SI-10/22/2010
506No prob, I'm a former RIGL long and back to following the stock closely agaimcbio-10/21/2010
505Niiiiiiiice summary, thanks! Transplant rejection has been a graveyard for manyscaram(o)uche-10/21/2010
504I posted relevant notes over on iHub (https://www.siliconinvestor.com/nfvda/boarmcbio-10/21/2010
503<i>that it has earned $25 million from AstraZeneca for the fulfillment of Steve Lokness-10/3/2010
502Rigel Earns Milestone Payments From AstraZenecaPR Newswire - Wednesday 09/29/201mopgcw-10/2/2010
501<i> significantly improved outcomes of patients with rheumatoid arthritis Steve Lokness-9/23/2010
500guess the market expected this... Data Published Today Reveal That Novel Oral Tmopgcw-9/23/2010
499I looked through my archives, and they did a presentation in March last year atmopgcw-9/9/2010
498Oncology being pursued with a newer compound R428. Not in the pipeline chart yetuck-9/9/2010
497thanks for the dig. RIGL is one I am still holding here, as I think it is stillmopgcw-9/5/2010
496Good to see something happening in the ligase program. This is old, but still stuck-9/3/2010
495[(R788) inhibits tumor growth in CLL by blocking antigen-dependent B cell recepttuck-8/19/2010
494Rigel Announces Second Quarter 2010 Financial Results SOUTH SAN FRANCISCO, Calimopgcw-8/5/2010
493CS: RIGL, PFE, LLY - Positive Data of of INCB28050 Reported 5/7/10 ! The Interimopgcw-5/8/2010
492citi: Rigel Pharmaceuticals Inc (RIGL) Uneventful 1Q 5/4/10 ? What’s New — RIGLmopgcw-5/8/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News